期刊
BLOOD COAGULATION & FIBRINOLYSIS
卷 15, 期 1, 页码 21-24出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00001721-200401000-00004
关键词
essential thrombocythemia; factor II; factor V; platelet glycoprotein, polycythemia vera
类别
资金
- NHLBI NIH HHS [HL65205] Funding Source: Medline
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065205] Funding Source: NIH RePORTER
Patients with polycythemia vera and essential thrombocythemia are at risk for thrombotic and bleeding complications. Currently, no diagnostic test can predict thrombohemorrhagic complications. In a prospective study of 86 patients with polycythemia vera (43 patients) or essential thrombocythemia (43 patients), we examined the possible role of polymorphisms of platelet adhesion receptors (glycoprotein (GP) Ibalpha, GPIa, GPIIIa) and clotting factor II (prothrombin's G20210A mutation) and clotting factor V (Leiden mutation) in determining the risk of thrombotic or bleeding complications. Except for an association between vasomotor symptoms and prothrombin mutation (P < 0.001), no significant correlation between polymorphism of clotting factors and thrombohemorrhagic complications was identified. When the entire patient cohort was considered, the polymorphisms of platelet adhesion receptors were not associated with the risk for thrombotic or bleeding complications. However, among patients with polycythemia vera, the presence of the pI(A2) allele of GPIIIa was associated with an increased risk of arterial thrombosis. In view of previous studies linking the presence of the pIA2 allele of GPIIIa to a higher risk for coronary artery thrombosis, our data have physiologic relevance. However, they need to be confirmed in a larger study. (C) 2004 Lippincott Williams Wilkins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据